The PCSK9 inhibitor lowered LDL cholesterol by 38{380aeddbf14a84cd11c11cd488112056163e30cadda676ce0194921ef8f43b08} vs placebo in HAUSER-RCT, the first randomized controlled trial of one of these agents in the pediatric population.
Medscape Medical News